ReviewDrugs2016
Non-Infectious Uveitis: Optimising the Therapeutic Response.
Review in Drugs, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- Efficacy and safety of adalimumab in the treatment of non-infectious uveitis: a meta-analysis and systematic review.Drug design, development and therapy · 2018Pooled it
- Self-assembled non-steroidal anti-inflammatory drug-peptide hydrogel to effectively mitigate ocular inflammation.Drug delivery · 2026Article
- Adrenomedullin-RAMP2 System Modulates Inflammation and Tissue Repair in Experimental Autoimmune Uveitis Via T-Cell and M2 Macrophage Regulation.Investigative ophthalmology & visual science · 2025Article
- Network pharmacology and molecular docking analyses of the Wuwei Mingmu formula indicate that IL-10 and IL-6 are critical targets against experimental autoimmune uveitis in rats.Frontiers in pharmacology · 2025Article
- Beneficial mechanisms of dimethyl fumarate in autoimmune uveitis: insights from single-cell RNA sequencing.Journal of neuroinflammation · 2024Article
- AAV-mediated gene therapies for glaucoma and uveitis: are we there yet?Expert reviews in molecular medicine · 2024Review
- Rheumatic diseases detected in patients presenting with uveitis.Northern clinics of Istanbul · 2024Article
- Rituximab in the Treatment of Non-Infectious Uveitis: A Review.Journal of inflammation research · 2024Review
- Immunopeptides: immunomodulatory strategies and prospects for ocular immunity applications.Frontiers in immunology · 2024Review
- Pathogenesis and current therapies for non-infectious uveitis.Clinical and experimental medicine · 2023Review
- Therapeutic Response After Immunosuppressive Drug Prescription in Non-infectious Uveitis: A Survival Analysis.Ophthalmology and therapy · 2023Article
- Development and Characterization of PEGylated Fatty Acid-Polymers · 2022Article
- Assessment of Anterior Uveitis Through Anterior-Segment Optical Coherence Tomography and Artificial Intelligence-Based Image Analyses.Translational vision science & technology · 2022Article
- Topical Anti-Inflammatory Agents for Non-Infectious Uveitis: Current Treatment and Perspectives.Journal of inflammation research · 2022Review
- A Review of the Various Roles and Participation Levels of B-Cells in Non-Infectious Uveitis.Frontiers in immunology · 2021Review
- Efficacy and Safety of Adalimumab in Noninfectious Uveitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Frontiers in pharmacology · 2021Review
- Cytokine Profiling in Aqueous Humor Samples From Patients With Non-Infectious Uveitis Associated With Systemic Inflammatory Diseases.Frontiers in immunology · 2020Article
- Toxicity and in vivo release profile of sirolimus from implants into the vitreous of rabbits' eyes.Documenta ophthalmologica. Advances in ophthalmology · 2019Article
- Management of chronic ocular sarcoidosis: challenges and solutions.Clinical ophthalmology (Auckland, N.Z.) · 2018Review
- Noninvasive Ocular Drug Delivery System of Dexamethasone Sodium Phosphate in the Treatment of Experimental Uveitis Rabbit.Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-infectious uveitis mainly affects the working-age population and can contribute to significant social and economic burden. It comprises a heterogeneous group of conditions with varied aetiology. Precise and early diagnosis, excluding masquerade syndromes, is the key to early therapeutic intervention. Treatment should be appropriately selected according to the anatomical sites of inflammation, the diagnosis and known prognosis, and whether there is a systemic inflammatory drive. Corticosteroids in the form of local or systemic therapy form the mainstay of treatment; however, due to unacceptable side effects, the need for long-term use or suboptimal response, corticosteroid-sparing medications may need to be considered early on in the management of non-infectious uveitis. With newer insights into the immunopathology of uveitis and the availability of biologic agents, treatment can be tailored according to individual needs. Many patients have systemic involvement, and hence a multidisciplinary approach is often required to achieve the best outcome in an individual. Patient involvement in the management of non-infectious uveitis, ensuring compliance, and continual monitoring of both the treatment and therapeutic response are the key to achieving optimal outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.